RESUMEN Fundamento: Los anticuerpos monoclonales son proteínas encargas del reconocimiento especifico de moléculas antigénicas que en las últimas décadas se han utilizado en el diagnóstico y tratamiento de diversas enfermedades, entre ellas el cáncer gástrico; sin embargo, aún no se tiene establecido un esquema terapéutico de primera línea con alguno de ellos. Se realizó una revisión de la literatura internacional en PubMed, SCOPUS y Medline de los artículos relacionados con el tratamiento del cáncer gástrico a base de anticuerpos monoclonales, utilizando las palabras claves, se incluyeron artículos en inglés, originales y revisiones, con no más de 10 años de antigüedad. Conclusión: existe una gran variedad de anticuerpos monoclonales que en diferentes estudios clínicos han demostrado tener un efecto favorable en la sobrevida y tasa de progresión de la enfermedad; sin embargo, algunos de ellos aún no han sido aprobados como tratamientos de primera línea para este padecimiento, debido a que faltan más evidencias sobre su seguridad y eficacia. ABSTRACT Monoclonal antibodies are proteins responsible for the specific recognition of antigenic molecules, in recent decades they have been used in the diagnosis and treatment of various diseases, including gastric cancer; however, a first-line therapeutic scheme has not yet been established with any of them. A review of the international literature in PubMed, SCOPUS and Medline of the articles related to the treatment of gastric cancer based on monoclonal antibodies is performed, in which the keywords were used, including articles in English, original and reviews, with no more than 10 years old. Conclusion: there are a wide variety of monoclonal antibodies that in diferent clinical studies have shown to have a favorable effect on the survival and rate of disease progression; however, some of them have not yet been approved as first-line treatments for this condition, due to the lack of more evidence about its safety and efficacy., {"references":["Afshari F, Soleyman-Jahi S, Keshavarz-Fathi M, et al. The promising role of monoclonal antibodies for gastric cáncer treatment. Immunotherapy. 2019; ll(4):347-64. https://d0i.0rg/l 0.2217/imt-2018-0093.","Pento JT. Monoclonal antibodies for the treatment of cáncer. Anticancer Research. 2017;37(ll):5935-39. https://doi.org/10.21873/anticanres. 12040.","Abbas AK, Lichtman AH, Pober JS, \"Inmunología celular y molecular\" 7o Ed. Elsevier Castellano, 2012. Anticuerpos y antígenos; 89-107.","García Merino A. Anticuerpos monoclonales. Aspectos básicos. Neurología. 2011; 26(5):301-6.","Hanack K, Messerschmidt K, Listek M. Antibodies and selection of monoclonal antibodies. In Adv Exp Med Biol. 2016;917:11-22. https://doi.org/10.1007/978-3-319-32805-82.","Parakh S, King D, Gan HK, et al. Current Development of Monoclonal Antibodies in Cáncer Therapy. Cáncer Res. [6] 2020;214:1-70. https://doi.org/10.1007/978-3-030-23765-3_l.","Shepard HM, Phillips GL, Thanos CD, et al. Developments in therapy with monoclonal antibodies and related proteins. Clin Med (London). 2017; 17(3):220-32. https://doi.org/10.7861/clinmedicine.17-3-220.","Coutzac C, Pernot S, Chaput N, et al. Immunotherapy in advanced gastric cáncer, is it the future? Cri Rev Oncol Hematol. \t2019;133:25-32. https://doi.Org/10.1016/j.critrevonc.2018.10.007.","Buss NAPS, Henderson SJ, McFarlane M, et al. Monoclonal antibody therapeutics: History and future. Curr Opin Pharmacol. \t2012;12(5):615-22. https://doi.Org/10.1016/j.coph.2012.08.001.","Zgodziñski W, Grywalska E, Surdacka A, et al. Surface CD200 and CD200R antigens on lymphocytes in advanced gastric cáncer: A new potential target for immunotherapy. Archives of Medical Science. 2018; 14(6):1271-80. https://doi.org/10.5114/aoms.2018.73398","Ralph C, Elkord E, Burt DJ, et al. Modulation of lymphocyte regulation for cáncer therapy: A phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clinical Cáncer Research. 2010; 16(5): 1662- 72. https://doi.Org/10.l 158/1078-0432.CCR-09-2870","Bang YJ, Cho JY, Kim YH, et al. Efficacy of sequential ipilimumab monotherapy versus best supportive care for unresectable locally advanced/metastatic gastric or gastroesophageal junction cáncer. Clinical Cáncer Research. 2017; 23(19):5671-78. https://doi.org/10.1158/1078-0432.CCR-17-0025","Togasaki K, Sukawa Y, Kanai T, et al. Clínica efficacy of immune checkpoint inhibitors in the treatment of unresectable advancd or recurrent gastric cáncer: an evidence-based review of therapies. Onco targets and ther. 2018;11:8239-50. https://doi.org/10.2147/ott.sl52514.","Gu L, Chen M, Guo D, et al. PD-L1 and gastric cáncer prognosis: A systematic review and meta-analysis. PLoS [6] ONE.2017;12(8):e0182692.https://doi.org/10.1371/joumal.po ne.0182692.","Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cáncer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2017; \t390(10111):2461-71. https://doi.org/! 0.1016/SO 140-6736(17)31827-5","Janjigian Y, Bendell J, Calvo E, et al. CheckMate-032 Study: Effícacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cáncer. J Clin Oncol. 2018;36:2836-44. https://doi.org/10.1200/JCG","Kamath SD, Kalyan A, Benson AB. Pembrolizumab for the treatment of gastric cáncer. Expert Review of Anticancer Therapy.2018;18(12):1177:87.https://doi.org/10.1080/147371 40.2018.1526084","Muro K, Chung HC, Shankaran,V, et al. Pembrolizumab for patients with PD-Ll-positive advanced gastric cáncer (KEYNOTE-012): a multicentre, open-label, phase Ib trial. The Lancet Oncology. 2016;17(6):717-26. https://doi.org/! 0.1016/S 1470-2045(16)00175-3","Shitara K, Ozgüroglu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cáncer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. The Lancet. 2018; 392(10142):123:33. \thttps://doi.org/10.1016/S0140-6736(18)31257-1","Doi T, Iwasa, S, Muro K, et al. Phase 1 trial of avelumab (anti-PD-Ll) in Japanese patients with advanced solid tumors, including dose expansión in patients with gastric or gastroesophageal junction cáncer: the JAVELIN Solid Tumor JPN trial. Gastric Cáncer. 2019;22(4):817-27. https://doi.org/! 0.1007/s 10120-018-0903-1","Chung HC, Arkenau HT, Lee J, et al. Avelumab (anti- PD-Ll) as fírst-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cáncer: Phase Ib results from the JAVELIN Solid Tumor trial. Journal for ImmunoTherapy of Cáncer. 2019; 7(1). https://doi.org/10.1186/s40425-019-0508-l","Bang YJ, Yafiez Ruiz E, van Cutsem E, et al. Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cáncer: Primary analysis of JAVELIN Gastric 300. Annals of Oncology .2018;29(10):2052-60. https://d0i.0rg/l 0.1093/annonc/mdy264","Leal AD, Krishnamurthy A, Head L et al. Antibody drug conjugales under investigation in phase I and phase II clinical triáis for gastrointestinal cáncer. Expert Opinión on Investigational \tDrugs. \t2018;27:901-16. https://doi.org/10.1080/13543784.2018.1541085","Sawaki A, Ohashi Y, Omuro Y, et al. Effícacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cáncer: A subgroup analysis of the Trastuzumab for Gastric Cáncer (ToGA) study. Gastric Cáncer. 2012;5(3):313-22. https://d0i.0rg/l 0.1007/s 10120-011-0118-1","Thuss-Patience PC, Shah MA, Ohtsu A, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an International randomised, open-label, adaptive, phase 2/3 study. The Lancet Oncology. 2017;18(5):640-53. https://d0i.0rg/l 0.1016/S 1470-2045(17)30111 -0","Kolberg H-C, Colleoni M, Santi P, et al. Totality of Scientifíc Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab. Targeted Oncology. 2019 https://doi.org/10.1007/sll523-019-00675-z","Pinto C, di Fabio F, Barone C, et al. Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). British Journal of Cáncer. 2009;101(8):1261-68. https://doi.org/10.1038/sj.bjc.6605319","Lordick F, Kang YK, Chung, HC, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cáncer (EXPAND): A randomised, open-label phase 3 trial. The Lancet Oncology. 2013;14(6):490-99. \thttps://doi.org/10.1016/S1470-2045(13)70102-5","Rao S, Starling N, Cunningham D, et al. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cáncer: A randomised, multicentre open-label phase II study. Annals of Oncology. \t2010;21(ll):2213-19. https://d0i.0rg/l 0.1093/annonc/mdq247","Waddell T, Chau I, Cunningham D, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cáncer (REAL3): A randomised, open-label phase 3 trial. The Lancet Oncology, 2013; 14(6):481-89.https://doi.org/! 0.1016/S1470-2045( 13)70096-2","Hironaka S. Anti-angiogenic therapies for gastric cáncer. Asia-Pacifíc Journal of Clinical Oncology. 2019;15:208-17. https://doi.0rg/lO.l 11 l/ajco.13174","Van Cutsem E, de Haas S, Kang YK, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cáncer: A biomarker evaluation from the AVAGAST randomized phase III trial. Journal of Clinical Oncology. 2012; 30(17):2119-27. https://doi.org/10.1200/JCO.2011.39.9824","Shen L, Li J, Xu J, et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cáncer: randomized, double-blind, phase III study (AVATAR study). Gastric Cáncer.\t2015;18(1): 168-76. https://d0i.0rg/l 0.1007/s 10120-014-03 51 -5","Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro- oesophageal junction adenocarcinoma (REGARD): An International, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet. 2014;383(9911):31-9. https://d0i.0rg/l 0.1016/SO140-6736(13)61719-5","Wilke H, Muro K, van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial. The Lancet Oncology. 2014; 15(11): 1224-35. https://doi.org/10.1016/S1470-2045(14)70420-6","Harding JJ, Zhu AX, Bauer TM, et al. A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cáncer. Clinical Cáncer Research. 2019;25(17):5202-ll. https://doi.org/10.1158/1078-0432.ccr- 18-4010","Hou W, Yuan Q, Yuan X, et al. A novel tetravalent bispecifíc antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cáncer. Investigational \tNew \tDrugs. \t2018; https://doi.org/10.1007/sl0637-018-0689-3","Kim, ST, Lee IK, Rom E, et al. Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cáncer with FGFR2 amplifícation. In Am J Transí Res. 2019; 11.","Osanai-Sasakawa A, Hosomi K, Sumitomo Y, et al. An anti-ASCT2 monoclonal antibody suppresses gastric cáncer growth by inducing oxidative stress and antibody dependent cellular toxicity in preclinical models. In Am J Cáncer Res. 2018;8.","Ding Y, Zhou J, Wang S, et al. Anti-neuropilin-1 monoclonal antibody suppresses the migration and invasión of human gastric cáncer cells via Akt dephosphorylation. Experimental and Therapeutic Medicine. 2018;16(2):537-46. https://doi.org/10.3892/etm.2018.6234","Han H, Wang S, Hu Y, et al. Monoclonal antibody 3H11 chimeric antigen receptors enhance T cell effector function and exhibit effícacy against gastric cáncer. Oncology Letters. 2018;15(5):6887-94. https://doi.org/10.3892/ol.2018.8255","Sahin U, Schuler M, Richly H, et al. A phase I dose- escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cáncer. European Journal of Cáncer. 2018;100:17-26. https://d0i.0rg/l 0.1016/j .ejca.2018.05.007","Türeci O, Sahin U, Schulze-Bergkamen H, et al. A multicentre, phase lia study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Annals of Oncology. 2019;30(9):1487-95. https://doi.org/! 0.1093/annonc/mdzl 99","Shah MA, Starodu, A, Sharma S, et al. Andecaliximab/GS-5745 alone and combined with FOLFOX6 in advanced gastric and gastroesophageal junction adenocarcinoma: Results from a phase I study. Clinical Cáncer Research. 2018; 24(16):3829-37. https://doi.org/! 0.115 8/1078-0432.CCR-17-2469"]}